Laura H.
- Country
- France
- Department
- Oncologie
Research Overview
- Phase 3 Randomized, Double-Blind Study of Tucatinib with Trastuzumab and Pertuzumab in Maintenance Therapy for Metastatic HER2-Positive Breast Cancer
- Evaluation of Tucatinib, Pertuzumab, and Trastuzumab in HER2-Positive Metastatic Breast Cancer with Isolated Brain Progression
- A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2−) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH−]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy
Data & Insights
Has run more than one trial at 35 of 137 partner sites.
Specializations
Advanced Breast Cancer Treatment
The investigator specializes in treating complex cases of metastatic breast cancer, with particular expertise in managing patients with brain metastases and various molecular subtypes of breast cancer.
- HER2-Positive Breast Cancer
- Brain Metastasis Management
- Targeted Therapy Combinations
Their research encompasses innovative therapeutic approaches for patients with HER2-positive breast cancer who have developed brain metastases.
Hormone Receptor-Positive Disease
The investigator focuses on developing treatment strategies for hormone receptor-positive, HER2-negative breast cancer, particularly in cases where standard endocrine therapy has been utilized.
- Endocrine Therapy Resistance
- Advanced Stage Disease
- Novel Therapeutic Approaches
Their work addresses the critical need for effective treatments in locally advanced or metastatic breast cancer cases that have progressed despite endocrine-based regimens.
Precision Medicine Applications
The investigator's work encompasses the application of targeted therapeutic agents in breast cancer treatment, with attention to specific molecular subtypes and resistance patterns.
- Molecular Subtype-Specific Treatment
- Treatment Sequencing Strategies
- Therapeutic Response Assessment
Their research involves evaluating novel therapeutic combinations and comparing treatment efficacy in different patient populations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.